On October 29, the state food and drug administration announced that from zhuhai pharmaceutical co., LTD., are creatures as BE research CRO (tumor hospital of hunan province is responsible for clinical, first brought the medicine is responsible for recruiting and SMO service, Jordan farmar ke data to perform data management and statistical analysis) of the Glenn nye approved production, this also is the national third approved successfully!
Nateglinide tablets are non-sulfonylurea insulin secreting agents. By binding to and closing atP-sensitive K+ channel receptors on the cell membrane, cells are depolarized, calcium channels are opened, and calcium influx is induced, thus stimulating insulin secretion and lowering blood glucose. It can be used alone in patients with type 2 diabetes who cannot effectively control hyperglycemia with diet and exercise, and in patients with type 2 diabetes who cannot effectively control hyperglycemia with metformin. According to CPA data of Chinese Pharmaceutical Society, the sales of Nateglinide tablets in the domestic sample market in 2018 reached 25.6788 million yuan.
As a "one-stop" service platform for clinical research of innovative drugs and generic drugs, Duzheng Biotech has helped many pharmaceutical companies to obtain successful approval. After July 22, the company carried out nearly 200 BE/PK projects, among which pantoprazole sodium enteric-coated tablets were approved first and second in China. The first donepezil hydrochloride tablet approved in China; Solina succinate new national third approved; Escitalopram oxalate was first approved in Hunan. At present, many new drugs and generic drugs are in clinical development.